Association Between Proton Pump Inhibitors and the Risk of Intestinal Behcet Disease

被引：0

作者：

Murakami, Keita ^{[1
]}

Arai, Junya ^{[1
,2
]}

Ihara, Sozaburo ^{[1
]}

Hirata, Yoshihiro ^{[1
,3
]}

Tsuchida, Yumi ^{[4
]}

Shoda, Hirofumi ^{[4
]}

Tsuboi, Mayo ^{[1
]}

Kurokawa, Ken ^{[1
]}

Suzuki, Nobumi ^{[1
]}

Kinoshita, Hiroto ^{[1
]}

Hayakawa, Yoku ^{[1
]}

Fujio, Keishi ^{[4
]}

Fujishiro, Mitsuhiro ^{[1
]}

机构：

[1] Univ Tokyo, Grad Sch Med, Dept Gastroenterol, Hongo 7-3-1,Bunkyo Ku, Tokyo 1138655, Japan

[2] Asahi Life Fdn, Inst Med Sci, Dept Gastroenterol, Tokyo, Japan

[3] Univ Tokyo, Inst Med Sci, Div Adv Genome Med, Tokyo, Japan

[4] Univ Tokyo, Grad Sch Med, Dept Allergy & Rheumatol, Tokyo, Japan

来源：

JOURNAL OF RHEUMATOLOGY | 2024年 / 51卷 / 12期

基金：

日本学术振兴会;

关键词：

Behcet disease; intestinal diseases; proton pump inhibitors;

D O I：

10.3899/jrheum.2024-0442

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Objective. This study aimed to investigate the association between proton pump inhibitor (PPI) use and the incidence of intestinal Beh & ccedil;et's disease (BD) in patients with BD. Methods. A retrospective cohort study was conducted at the University of Tokyo Hospital, including BD patients diagnosed between April 2005 and November 2023. Cox models and Kaplan-Meier analyses were utilized to evaluate hazard ratios (HRs) and cumulative incidence of intestinal BD, respectively. Secondary analyses were performed to assess the duration and dose-response relationship of PPI use. Results. Among 194 BD patients, 25.3% developed intestinal BD during a mean followup of 12 years. PPI users exhibited a significantly higher incidence of intestinal BD compared to non-users (adjusted HR 2.48, 95% CI 1.38-4.47, P = 0.0024), with a confirmed duration/dose-dependent relationship. The cumulative incidence of intestinal BD was markedly elevated in PPI users (Log rank P < 0.001). The result was similar to that in the Propensity score-matched cohort. Conclusion. The study demonstrates a significant association between PPI use and increased incidence of intestinal BD in BD patients. Caution in prescribing PPIs for BD patients is warranted due to the potential risk of severe complications associated with intestinal BD.

引用

页码：1193 / 1197

页数：5

共 16 条

[1] Leonardo NM, McNeil J., Behcet’s disease: is there geographical variation? A review far from the silk road, Int J Rheumatol, 2015, (2015)
[2] Okubo M, Sumitomo S, Tsuchida Y, Et al., Transcriptome analysis of immune cells from Behçet’s syndrome patients: the importance of IL-17-producing cells and antigen-presenting cells in the pathogenesis of Behçet’s syndrome, Arthritis Res Ther, 24, (2022)
[3] Xia B, Yang M, Nguyen LH, Et al., Regular use of proton pump inhibitor and the risk of inflammatory bowel disease: pooled analysis of 3 prospective cohorts, Gastroenterology, 161, pp. 1842-1852, (2021)
[4] Nagata N, Nishijima S, Miyoshi-Akiyama T, Et al., Population-level metagenomics uncovers distinct effects of multiple medications on the human gut microbiome, Gastroenterology, 163, pp. 1038-1052, (2022)
[5] Criteria for diagnosis of Behçet’s disease. International Study Group for Behçet’s Disease, Lancet, 335, pp. 1078-1080, (1990)
[6] Suzuki Kurokawa M, Suzuki N., Behcet’s disease, Clin Exp Med, 4, pp. 10-20, (2004)
[7] Murakami K, Arai J, Ihara S, Et al., Upper gastrointestinal involvement of Behçet’s disease in Japan: endoscopic findings and clinical features, J Gastroenterol Hepatol, 39, pp. 708-715, (2024)
[8] Arai J, Miyawaki A, Aoki T, Et al., Association between Vonoprazan and the risk of gastric cancer after Helicobacter pylori eradication, Clin Gastroenterol Hepatol, 22, pp. 1217-1225, (2024)
[9] Xia B, He Q, Smith FG, Et al., Individualized prevention of proton pump inhibitor related adverse events by risk stratification, Nat Commun, 15, (2024)
[10] Lin CY, Cheng HT, Kuo CJ, Et al., Proton pump inhibitor-induced gut dysbiosis increases mortality rates for patients with Clostridioides difficile infection, Microbiol Spectr, 10, (2022)

← 1 2 →